Gene expression profiling following short-term and long-term morphine exposure in mice uncovers genes involved in food intake

Neuroscience

Volumn 167, Issue 2, 2010, Pages 554-566

  Anghel, A ^a,b   Jamieson, C A M ^b   Ren, X ^a   Young, J ^a,c   Porche, R ^a   Ozigbo, E ^a   Ghods, D E ^a   Lee, M L ^a   Liu, Y ^a   Lutfy, K ^a,d   Friedman, T C ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Food intake; Hypothalamus; Microarray; Opiates; Pituitary; RT PCR

Indexed keywords

AGOUTI RELATED PROTEIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; MORPHINE; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EXPOSURE; EXPOSURE; FOOD INTAKE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HYPOPHYSIS; HYPOTHALAMUS; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT TERM EXPOSURE; UPREGULATION;

ANIMALS; BODY WEIGHT; EATING; GENE EXPRESSION PROFILING; HYPOTHALAMUS; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PITUITARY GLAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 77950864643     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.01.043     Document Type: Article

References (67)

1. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
2. Ammon S., Mayer P., Riechert U., Tischmeyer H., Hollt V. Microarray analysis of genes expressed in the frontal cortex of rats chronically treated with morphine and after naloxone precipitated withdrawal. Brain Res Mol Brain Res 2003, 112:113-125.
3. Ammon-Treiber S., Grecksch G., Stumm R., Riechert U., Tischmeyer H., Reichenauer A., Hollt V. Rapid, transient, and dose-dependent expression of hsp70 messenger RNA in the rat brain after morphine treatment. Cell Stress Chaperones 2004, 9:182-197.
4. Ammon-Treiber S., Hollt V. Morphine-induced changes of gene expression in the brain. Addict Biol 2005, 10:81-89.
5. Ammon-Treiber S., Tischmeyer H., Riechert U., Hollt V. Gene expression of transcription factors in the rat brain after morphine withdrawal. Neurochem Res 2004, 29:1267-1273.
6. Baker H., Joh T.H., Ruggiero D.A., Reis D.J. Variations in number of dopamine neurons and tyrosine hydroxylase activity in hypothalamus of two mouse strains. J Neurosci 1983, 3:832-843.
7. Befort K., Filliol D., Darcq E., Ghate A., Matifas A., Lardenois A., Muller J., Thibault C., Dembele D., Poch O., Kieffer B.L. Gene expression is altered in the lateral hypothalamus upon activation of the mu opioid receptor. Ann N Y Acad Sci 2008, 1129:175-184.
8. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1988, 72:248-254.
9. Brakch N., Rist B., Beck-Sickinger A.G., Goenaga J., Wittek R., Burger E., Brunner H.R., Grouzmann E. Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations. Biochemistry (Mosc) 1997, 36:16309-16320.
10. Cawley N.X., Zhou J., Hill J.M., Abebe D., Romboz S., Yanik T., Rodriguiz R.M., Wetsel W.C., Loh Y.P. The carboxypeptidase E knockout mouse exhibits endocrinological and behavioral deficits. Endocrinology 2004, 145:5807-5819.
11. Chao J., Nestler E.J. Molecular neurobiology of drug addiction. Annu Rev Med 2004, 55:113-132.
12. Chen G., Bridenbaugh E.A., Akintola A.D., Catania J.M., Vaidya V.S., Bonventre J.V., Dearman A.C., Sampson H.W., Zawieja D.C., Burghardt R.C., Parrish A.R. Increased susceptibility of aging kidney to ischemic injury: identification of candidate genes changed during aging, but corrected by caloric restriction. Am J Physiol Renal Physiol 2007, 293:F1272-F1281.
13. Chen M., Celik A., Georgeson K.E., Harmon C.M., Yang Y. Molecular basis of melanocortin-4 receptor for AGRP inverse agonism. Regul Pept 2006, 136:40-49.
14. Cooper S.J. Behaviourally-specific hyperdipsia in the non-deprived rat following acute morphine treatment. Neuropharmacology 1981, 20:469-471.
15. Cooper S.J., Sanger D.J. Endorphinergic mechanisms in food, salt and water intake: an overview. Appetite 1984, 5:1-6.
16. Creemers J.W., Pritchard L.E., Gyte A., Le Rouzic P., Meulemans S., Wardlaw S.L., Zhu X., Steiner D.F., Davies N., Armstrong D., Lawrence C.B., Luckman S.M., Schmitz C.A., Davies R.A., Brennand J.C., White A. Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP) 83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3. Endocrinology 2006, 147:1621-1631.
17. Dey A., Xhu X., Carroll R., Turck C.W., Stein J., Steiner D.F. Biological processing of the cocaine and amphetamine-regulated transcript precursors by prohormone convertases, PC2 and PC1/3. J Biol Chem 2003, 278:15007-15014.
18. Dylag T., Kotlinska J., Rafalski P., Pachuta A., Silberring J. The activity of CART peptide fragments. Peptides 2006, 27:1926-1933.
19. Eipper B.A., Mains R.E. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. Endocr Rev 1980, 1:1-27.
20. Espinosa V.P., Liu Y., Ferrini M., Anghel A., Nie Y., Tripathi P.V., Porche R., Jansen E., Stuart R.C., Nillni E.A., Lutfy K., Friedman T.C. Differential regulation of prohormone convertase 1/3, prohormone convertase 2 and phosphorylated cyclic-AMP-response element binding protein by short-term and long-term morphine treatment: implications for understanding the "switch" to opiate addiction. Neuroscience 2008, 156:788-799.
21. Frenk H., Rogers G.H. The suppressant effects of naloxone on food and water intake in the rat. Behav Neural Biol 1979, 26:23-40.
22. Garcia de Yebenes E., Pelletier G. Opioid regulation of proopiomelanocortin (POMC) gene expression in the rat brain as studied by in situ hybridization. Neuropeptides 1993, 25:91-94.
23. Gerrits M.A., Lesscher H.B., van Ree J.M. Drug dependence and the endogenous opioid system. Eur Neuropsychopharmacol 2003, 13:424-434.
24. Grander D., Sangfelt O., Skoog L., Hansson J. In vivo induction of the interferon-stimulated protein 2'5'-oligoadenylate synthetase in tumor and peripheral blood cells during IFN-alpha treatment of metastatic melanoma. J Interferon Cytokine Res 1998, 18:691-695.
25. Grandison L., Guidotti A. Stimulation of food intake by muscimol and beta endorphin. Neuropharmacology 1977, 16:533-536.
26. Grice D.E., Reenila I., Mannisto P.T., Brooks A.I., Smith G.G., Golden G.T., Buxbaum J.D., Berrettini W.H. Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics 2007, 8:76.
27. Kinashi T., Harada N., Severinson E., Tanabe T., Sideras P., Konishi M., Azuma C., Tominaga A., Bergstedt-Lindqvist S., Takahashi M., et al. Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II. Nature 1986, 324:70-73.
28. Koob G.F., Ahmed S.H., Boutrel B., Chen S.A., Kenny P.J., Markou A., O'Dell L.E., Parsons L.H., Sanna P.P. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 2004, 27:739-749.
29. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
30. Korostynski M., Piechota M., Kaminska D., Solecki W., Przewlocki R. Morphine effects on striatal transcriptome in mice. Genome Biol 2007, 8:R128.
31. Kotlinska J., Pachuta A., Dylag T., Silberring J. The role of neuropeptide FF (NPFF) in the expression of sensitization to hyperlocomotor effect of morphine and ethanol. Neuropeptides 2007, 41:51-58.
32. Kreek M.J., Schlussman S.D., Bart G., Laforge K.S., Butelman E.R. Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. Neuropharmacology 2004, 47(Suppl 1):324-344.
33. Kunihara M., Kanbayashi M., Ohshima T. Opposite effects of morphine on feeding and drinking in rats relative to administration time. Jpn J Pharmacol 1983, 33:829-835.
34. Leshem M. Morphine-induced anorexia in lateral hypothalamic rats. Psychopharmacology (Berl) 1981, 75:48-53.
35. Leshem M. Morphine induces delayed anorexia in rats. Psychopharmacology (Berl) 1988, 94:254-258.
36. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
37. Levine A.S., Morley J.E., Gosnell B.A., Billington C.J., Bartness T.J. Opioids and consummatory behavior. Brain Res Bull 1985, 14:663-672.
38. Lewcock J.W., Reed R.R. A feedback mechanism regulates monoallelic odorant receptor expression. Proc Natl Acad Sci U S A 2004, 101:1069-1074.
39. Li J.Y., Lescure P.A., Misek D.E., Lai Y.M., Chai B.X., Kuick R., Thompson R.C., Demo R.M., Kurnit D.M., Michailidis G., Hanash S.M., Gantz I. Food deprivation-induced expression of minoxidil sulfotransferase in the hypothalamus uncovered by microarray analysis. J Biol Chem 2002, 277:9069-9076.
40. Lockhart D.J., Winzeler E.A. Genomics, gene expression and DNA arrays. Nature 2000, 405:827-836.
41. Loguinov A.V., Anderson L.M., Crosby G.J., Yukhananov R.Y. Gene expression following acute morphine administration. Physiol Genomics 2001, 6:169-181.
42. Marks-Kaufman R., Kanarek R.B. Morphine selectively influences macronutrient intake in the rat. Pharmacol Biochem Behav 1980, 12:427-430.
43. Marquez P., Baliram R., Gajawada N., Friedman T.C., Lutfy K. Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine. Behav Neurosci 2006, 120:10-15.
44. McClung C.A., Nestler E.J., Zachariou V. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. J Neurosci 2005, 25:6005-6015.
45. Morley J.E. The endocrinology of the opiates and opioid peptides. Metabolism 1981, 30:195-209.
46. Morley J.E., Levine A.S., Gosnell B.A., Billington C.J. Which opioid receptor mechanism modulates feeding?. Appetite 1984, 5:61-68.
47. Niemann A., Ruegg M., La Padula V., Schenone A., Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 2005, 170:1067-1078.
48. Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides 2004, 38:267-275.
49. Robbins T.W., Everitt B.J. Drug addiction: bad habits add up. Nature 1999, 398:567-570.
50. Rodriguez de Fonseca F., Carrera M., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
51. Roy S., Guo X., Kelschenbach J., Liu Y., Loh H.H. In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci 2005, 25:3229-3233.
52. Sanger D.J., McCarthy P.S. Differential effects of morphine on food and water intake in food deprived and freely-feeding rats. Psychopharmacology (Berl) 1980, 72:103-106.
53. Schwartz M.W. Brain pathways controlling food intake and body weight. Exp Biol Med (Maywood) 2001, 226:978-981.
54. Seidah N.G., Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 1999, 848:45-62.
55. Soverchia L., Ubaldi M., Leonardi-Essmann F., Ciccocioppo R., Hardiman G. Microarrays-the challenge of preparing brain tissue samples. Addict Biol 2005, 10:5-13.
56. Spangler R., Zhou Y., Maggos C.E., Zlobin A., Ho A., Kreek M.J. Dopamine antagonist and "binge" cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport 1996, 7:2196-2200.
57. Spijker S., Houtzager S.W., De Gunst M.C., De Boer W.P., Schoffelmeer A.N., Smit A.B. Morphine exposure and abstinence define specific stages of gene expression in the rat nucleus accumbens. FASEB J 2004, 18:848-850.
58. Stehlik C., Lee S.H., Dorfleutner A., Stassinopoulos A., Sagara J., Reed J.C. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 2003, 171:6154-6163.
59. Stein J., Shah R., Steiner D.F., Dey A. RNAi-mediated silencing of prohormone convertase (PC) 5/6 expression leads to impairment in processing of cocaine- and amphetamine-regulated transcript (CART) precursor. Biochem J 2006, 400:209-215.
60. Sturn A., Quackenbush J., Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002, 18:207-208.
61. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004, 9:557-569.
62. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC (in press) The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev.
63. Wang X., Seed B. Selection of oligonucleotide probes for protein coding sequences. Bioinformatics 2003, 19:796-802.
64. Wolgin D.L., Benson H.D. Role of associative and nonassociative mechanisms in tolerance to morphine "anorexia". Pharmacol Biochem Behav 1991, 39:279-286.
65. Zhang L., Lou D., Jiao H., Zhang D., Wang X., Xia Y., Zhang J., Xu M. Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors. J Neurosci 2004, 24:3344-3354.
66. Zhou A., Bloomquist B.T., Mains R.E. The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 1993, 268:1763-1769.
67. Zhou Y., Spangler R., LaForge K.S., Maggos C.E., Ho A., Kreek M.J. Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 1996, 279:351-358.